Natalizumab efficacy on cognitive impairment in MS
- PMID: 20535512
- DOI: 10.1007/s10072-010-0351-0
Natalizumab efficacy on cognitive impairment in MS
Abstract
We report follow-up data on the efficacy of natalizumab therapy on neuropsychological impairment on an italian MS group of 39 patients at 1 year and of 11 patients at 2 years. Results show a significant reduction in relapse rate, in the number of impaired neuropsychological tests as well as in several single executive function and reasoning tests scores at 1 year. Improvement persisted at 2 years, including also memory and speed processing tasks. These data support the efficacy of natalizumab therapy in all the clinical domains, including cognitive deterioration, in multiple sclerosis patients.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
